Skip to main
HCA
HCA logo

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare (HCA) Analyst Ratings

Based on 39 analyst ratings
Buy
Strong Buy 36%
Buy 38%
Hold 23%
Sell 3%
Strong Sell 0%

Bulls say

HCA Healthcare's EBITDA in the fourth quarter of 2024 demonstrated resilience, growing over 6% when excluding the impact of state DPPs and accounting for hurricane effects, indicating robust operational performance. The company experienced significant growth in same-store inpatient surgeries, with a year-over-year increase of 180 basis points, reflecting strong demand and management's effective execution strategies. Furthermore, HCA's substantial market presence, characterized by an unmatched scale and infrastructure, positions it favorably for continued market share gains and enhances its outlook within the competitive healthcare landscape.

Bears say

HCA Healthcare's stock outlook is negatively impacted by uncertainties surrounding Medicaid direct payment programs and a projected decline in equivalent admissions for 2025. The firm anticipates headwinds from various factors including non-recurrence of leap year effects and regulatory challenges, resulting in a lowered adjusted EBITDA estimate to $14.58 billion. Additionally, the market faces potential multiple compression, which undermines the positive re-rating the company has experienced in recent years, highlighting a turbulent financial landscape ahead.

HCA Healthcare (HCA) has been analyzed by 39 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 38% recommend Buy, 23% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HCA Healthcare (HCA) Forecast

Analysts have given HCA Healthcare (HCA) a Buy based on their latest research and market trends.

According to 39 analysts, HCA Healthcare (HCA) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $281.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $281.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HCA Healthcare (HCA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.